StockData
Relay Therapeutics, Inc. logo

Relay Therapeutics, Inc. (RLAY) shareholders

RLAYNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 10/30
$16.47−0.80 (-4.63%)

Close on Nov 17, 2026Market cap $3.61BP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
100.0%
247M of 219M shares
Institutional holders
258
51 new, 31 sold out
Net institutional buying
62M
In Q2 2026
Insider trades, 12 months
0 buys · 39 sales
Net sold $129.18M

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
FMR LLC
Joint filing with Abigail P. Johnson (10.00%)
21,270,75110.00%13G (passive) amendmentJul 31, 2026
Perceptive Advisors LLC
Joint filing with Joseph Edelman (6.40%), Perceptive Life Sciences Master Fund, Ltd. (6.40%)
14,106,1876.40%13G (passive) amendmentJun 30, 2026
Point72 Asset Management, L.P.
Joint filing with Point72 Capital Advisors, Inc. (7.80%), Steven A. Cohen (7.80%)
13,445,7047.80%13G (passive) amendmentJun 30, 2025
Michael Kramarz
Joint filing with Commodore Capital LP (7.80%), Commodore Capital Master LP (7.80%) and 1 more
13,350,0007.80%13G (passive) amendmentJun 30, 2025
Eli Casdin
Joint filing with Casdin Capital, LLC (7.50%), Casdin Partners Gp, LLC (7.50%) and 1 more
13,003,5747.50%13G (passive) amendmentDec 31, 2025
Casdin Capital, LLC
Joint filing with Casdin Partners Gp, LLC (7.50%), Eli Casdin (7.50%) and 1 more
13,003,5747.50%13G (passive) amendmentDec 31, 2025
Robert Egen Atkinson
Joint filing with Commodore Capital LP (5.50%), Commodore Capital Master LP (5.50%) and 1 more
12,000,0005.50%13G (passive) amendmentJun 30, 2026
BlackRock, Inc.10,308,0126.10%13G (passive) amendmentMar 31, 2025
Commodore Capital Master LP
Joint filing with Commodore Capital LP (5.80%)
10,000,0005.80%13G (passive)May 8, 2025
Point72 Capital Advisors, Inc.
Joint filing with Point72 Asset Management, L.P. (5.70%), Steven A. Cohen (5.70%)
9,694,2175.70%13G (passive)Mar 14, 2025
Joseph Edelman
Joint filing with Perceptive Advisors LLC (9.99%), Perceptive Life Sciences Master Fund, Ltd. (9.99%)
438,4719.99%13G (passive)Apr 6, 2026

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of RLAYValueChange% of portfolio
Sb Investment Advisers (Uk) Ltd27,904,96312.73%$522.10M–6.81%
FMR LLC20,110,1139.18%$376.26M+16,414,6820.02%
Casdin Capital, LLC16,035,2407.32%$300.02M+1,616,66615.02%
BlackRock, Inc.15,288,2026.98%$286.04M+2,312,9030.00%
Perceptive Advisors LLC14,106,1876.44%$263.93M+4,355,0463.96%
Commodore Capital LP12,000,0005.48%$224.52M−5,000,00013.37%
State Street Corp10,125,3814.62%$189.47M+3,891,8360.01%
Vanguard Capital Management LLC8,964,4234.09%$167.72M+1,576,9580.00%
Price T Rowe Associates Inc /Md/7,708,5073.52%$144.23M+5,783,5690.01%
Nextech Invest, Ltd.6,776,5063.09%$126.79M+1,250,0006.02%
Bellevue Group AG6,185,9702.82%$115.74M−1,609,2722.44%
Geode Capital Management, LLC4,726,5762.16%$88.45M+1,215,9400.00%
TCG Crossover Management, LLC4,273,3561.95%$79.95M–1.92%
Alliancebernstein L.P.4,095,6001.87%$40.75M+3,950,3490.01%
Morgan Stanley3,851,0711.76%$72.05M+2,419,0680.00%
Siren, L.L.C.3,650,0001.67%$68.29MNew1.38%
Goldman Sachs Group Inc3,408,7011.56%$63.78M+866,8400.01%
Westfield Capital Management Co LP3,343,4961.53%$62.56MNew0.20%
Kynam Capital Management, LP3,300,0001.51%$61.74M+1,875,7413.41%
Dimensional Fund Advisors LP3,127,5641.43%$58.53M+187,0280.01%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 2026258247M100.0%51 / 11564 / 3183M21M
Q1 2026244185M84.5%51 / 9653 / 3044M24M
Q4 2025227174M79.4%50 / 6857 / 2023M16M
Q3 2025199167M76.0%20 / 6363 / 2611M15M
Q2 2025208171M78.2%36 / 7256 / 3426M22M
Q1 2025207167M76.4%36 / 7359 / 2423M15M
Q4 2024199164M74.8%43 / 8736 / 3726M31M
Q3 2024195169M77.3%46 / 7246 / 2856M8M
Q2 2024179132M60.3%22 / 7550 / 3012M18M
Q1 2024189138M63.1%31 / 7350 / 1920M15M
Q4 2023177134M61.2%33 / 5557 / 2519M16M
Q3 2023172130M59.5%23 / 6747 / 129M9M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

260 funds held RLAY in Q2 2026, 48% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of RLAYValue% of fundAs of
Vanguard Total Stock Market Index Fund6,800,0833.10%$127.23M0.01%Jun 30, 2026
State Street(R) SPDR(R) S&P(R) Biotech ETF6,304,7012.88%$117.96M1.10%Jun 30, 2026
iShares Russell 2000 ETF4,163,6461.90%$77.90M0.09%Jun 30, 2026
Vanguard Extended Market Index Fund1,943,7880.89%$36.37M0.04%Jun 30, 2026
Fidelity Small Cap Growth Fund1,917,7500.88%$36.11M0.41%Jul 31, 2026
Fidelity Advisor Biotechnology Fund1,850,7000.84%$34.85M1.58%Jul 31, 2026
T. Rowe Price Health Sciences Fund, Inc.1,840,8960.84%$34.44M0.29%Jun 30, 2026
Fidelity Small Cap Index Fund1,767,8340.81%$33.29M0.10%Jul 31, 2026
Harbor Small Cap Growth Fund1,681,0000.77%$31.65M1.19%Jul 31, 2026
Fidelity Stock Selector Small Cap Fund1,680,4150.77%$31.64M0.43%Jul 31, 2026
Select Health Care Portfolio1,680,0000.77%$23.60M0.41%May 31, 2026
T. Rowe Price New Horizons Fund, Inc.1,574,1520.72%$29.45M0.20%Jun 30, 2026
T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund1,366,6110.62%$25.57M0.26%Jun 30, 2026
Strategic Advisers Fidelity U.S. Total Stock Fund1,285,4000.59%$18.06M0.01%May 31, 2026
iShares Russell 2000 Growth ETF1,128,8100.52%$21.12M0.14%Jun 30, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Sanjiv PatelPresident and CEO, Director1,358,2040.62%Oct 8, 2026
Donald A. BergstromPresident, R&D396,8780.18%Oct 30, 2026
Thomas CatinazzoChief Financial Officer103,6650.05%Oct 30, 2026
Peter RahmerSee remarks222,9040.10%Oct 30, 2026
Brian AdamsChief Legal Officer371,4720.17%Jul 30, 2025
Alexis BorisyDirector234,1750.11%Jun 10, 2026
Mark MurckoDirector996,9520.45%Jun 10, 2026
Claire MazumdarDirector––Jun 10, 2026
Habib J. DableDirector––Jun 10, 2026
Linda A. HillDirector––Jun 10, 2026
Lonnel CoatsDirector––Jun 10, 2026
Douglas S. IngramDirector25,0000.01%Jun 10, 2026
Sekar KathiresanDirector––Jun 6, 2025
Jami RubinDirector67,2420.03%Jun 6, 2025
Vision Fund (Aiv M2) L.P. Softbank10% owner––Aug 28, 2026
Pauling (Cayman) Ltd SVF10% owner27,904,96312.73%Aug 28, 2026
Investment Advisers (Uk) Ltd Sb10% owner21,904,96310.00%Aug 28, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Peter Rahmer
See remarks
Oct 28, 2026Sale−753$18.62$14.02K222,904
Donald A. Bergstrom
President, R&D
Oct 28, 2026Sale−2,252$18.62$41.93K396,878
Thomas Catinazzo
Chief Financial Officer
Oct 28, 2026Sale−1,469$18.62$27.35K103,665
Sanjiv Patel
President and CEO, Director
Oct 7, 2026Sale(10b5-1 plan)−48,199$18.10$872.40K471,301
Thomas Catinazzo
Chief Financial Officer
Oct 6, 2026Sale(10b5-1 plan)−206$19.26$3.97K105,134
Thomas Catinazzo
Chief Financial Officer
Oct 6, 2026Sale(10b5-1 plan)−17,511$18.58$325.35K105,340
Thomas Catinazzo
Chief Financial Officer
Sep 8, 2026Sale(10b5-1 plan)−17,717$18.94$335.56K122,851
Donald A. Bergstrom
President, R&D
Sep 8, 2026Sale(10b5-1 plan)−8,530$18.97$161.81K399,130
Sanjiv Patel
President and CEO, Director
Sep 8, 2026Sale(10b5-1 plan)−48,199$18.94$912.89K519,500
Peter Rahmer
See remarks
Aug 26, 2026Sale(10b5-1 plan)−4,508$20.03$90.30K223,657
Investment Advisers (Uk) Ltd Sb
10% owner
Aug 25, 2026Sale−6,000,000$19.40$116.40M21,904,963
Sanjiv Patel
President and CEO, Director
Aug 17, 2026Sale(10b5-1 plan)−48,199$20.33$979.89K567,699
Thomas Catinazzo
Chief Financial Officer
Aug 14, 2026Sale(10b5-1 plan)−17,717$19.74$349.73K140,568
Thomas Catinazzo
Chief Financial Officer
Jul 28, 2026Sale−1,459$18.61$27.15K158,285
Donald A. Bergstrom
President, R&D
Jul 28, 2026Sale−2,237$18.61$41.63K407,660
Peter Rahmer
See remarks
Jul 28, 2026Sale−748$18.61$13.92K228,165
Sanjiv Patel
President and CEO, Director
Jul 7, 2026Sale(10b5-1 plan)−48,199$19.58$943.74K615,898
Thomas Catinazzo
Chief Financial Officer
Jul 6, 2026Sale(10b5-1 plan)−17,717$18.69$331.13K159,744
Donald A. Bergstrom
President, R&D
Jul 6, 2026Sale(10b5-1 plan)−8,660$18.71$162.03K409,897
Sanjiv Patel
President and CEO, Director
Jun 30, 2026Award+3,056$6.95$21.24K664,097
Peter Rahmer
See remarks
Jun 30, 2026Sale(10b5-1 plan)−50,000$19.09$954.50K225,857
Peter Rahmer
See remarks
Jun 30, 2026Award+3,056$6.95$21.24K228,913
Thomas Catinazzo
Chief Financial Officer
Jun 22, 2026Sale(10b5-1 plan)−17,717$17.01$301.37K177,461
Thomas Catinazzo
Chief Financial Officer
Jun 22, 2026Option exercise+56,323$5.04$283.87K233,784
Thomas Catinazzo
Chief Financial Officer
Jun 22, 2026Sale(10b5-1 plan)−51,560$16.97$874.97K177,461
Thomas Catinazzo
Chief Financial Officer
Jun 22, 2026Option exercise+51,560$4.45$229.44K229,021
Thomas Catinazzo
Chief Financial Officer
Jun 22, 2026Sale(10b5-1 plan)−61,563$16.97$1.04M177,461
Thomas Catinazzo
Chief Financial Officer
Jun 22, 2026Option exercise+61,563$5.22$321.36K239,024
Thomas Catinazzo
Chief Financial Officer
Jun 22, 2026Sale(10b5-1 plan)−56,323$16.97$955.80K177,461
Donald A. Bergstrom
President, R&D
Jun 22, 2026Option exercise+93,456$4.12$385.04K512,013
Donald A. Bergstrom
President, R&D
Jun 22, 2026Sale(10b5-1 plan)−93,456$16.94$1.58M418,557
Thomas Catinazzo
Chief Financial Officer
May 14, 2026Sale(10b5-1 plan)−17,717$12.86$227.84K195,178
Donald A. Bergstrom
President, R&D
Apr 28, 2026Sale−1,490$14.79$22.04K418,557
Peter Rahmer
See remarks
Apr 28, 2026Sale−753$14.79$11.14K275,857
Thomas Catinazzo
Chief Financial Officer
Apr 28, 2026Sale−972$14.79$14.38K212,895
Thomas Catinazzo
Chief Financial Officer
Apr 9, 2026Option exercise+1,800$5.22$9.40K215,667
Thomas Catinazzo
Chief Financial Officer
Apr 9, 2026Sale(10b5-1 plan)−1,800$15.00$27.00K213,867
Thomas Catinazzo
Chief Financial Officer
Apr 7, 2026Sale(10b5-1 plan)−17,717$13.01$230.50K213,867
Thomas Catinazzo
Chief Financial Officer
Mar 9, 2026Sale(10b5-1 plan)−17,717$10.06$178.23K231,584
Peter Rahmer
See remarks
Jan 28, 2026Sale−1,354$8.45$11.44K276,610
Donald A. Bergstrom
President, R&D
Jan 28, 2026Sale−2,686$8.45$22.70K420,047
Thomas Catinazzo
Chief Financial Officer
Jan 28, 2026Sale−1,695$8.45$14.32K249,301
Peter Rahmer
See remarks
Jan 27, 2026Sale−11,684$7.62$89.03K277,964
Donald A. Bergstrom
President, R&D
Jan 27, 2026Sale−18,895$7.62$143.98K422,733
Thomas Catinazzo
Chief Financial Officer
Jan 27, 2026Sale−13,820$7.62$105.31K250,996
Sanjiv Patel
President and CEO, Director
Jan 6, 2026Sale−43,168$7.82$337.57K661,041
Peter Rahmer
See remarks
Dec 31, 2025Award+994$2.99$2.97K338,463
Sanjiv Patel
President and CEO, Director
Dec 31, 2025Award+994$2.99$2.97K704,209
Sanjiv Patel
President and CEO, Director
Nov 3, 2025Sale−62,073$7.00$434.51K703,215
Peter Rahmer
See remarks
Oct 29, 2025Sale−21,394$7.50$160.46K337,469
Thomas Catinazzo
Chief Financial Officer
Oct 28, 2025Sale−21,664$7.29$157.93K313,631
Peter Rahmer
See remarks
Oct 28, 2025Sale−19,135$7.29$139.49K358,863
Donald A. Bergstrom
President, R&D
Oct 28, 2025Sale−30,897$7.29$225.24K521,823
Brian Adams
Chief Legal Officer
Jul 29, 2025Sale−18,276$3.68$67.26K371,472
Thomas Catinazzo
Chief Financial Officer
Jul 29, 2025Sale−18,380$3.68$67.64K335,295
Peter Rahmer
See remarks
Jul 29, 2025Sale−15,724$3.68$57.86K377,998
Donald A. Bergstrom
President, R&D
Jul 29, 2025Sale−26,701$3.68$98.26K552,720
Brian Adams
Chief Legal Officer
Jul 28, 2025Sale−1,637$3.74$6.12K389,748
Thomas Catinazzo
Chief Financial Officer
Jul 28, 2025Sale−1,701$3.74$6.36K353,675
Peter Rahmer
See remarks
Jul 28, 2025Sale−1,359$3.74$5.08K393,722

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
26.35%
44M shares short
Days to cover
20.7
At 2M shares a day
Change since last report
-0.9%
From 44M shares
Short volume, 20 days
53.7%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Relay Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 440,875 shares on Oct 13, 2026 over the last 90 days.

Planned insider sales

Notices of proposed sale filed on Form 144 before shares are sold

SellerFiledSharesMarket valuePlanned saleAcquired through
Sanjiv Patel
Director, Officer
Oct 7, 202696,401$1.81MOct 7, 2026Restricted Stock Units
Thomas Catinazzo
Officer
Oct 6, 202693,153$1.81MOct 6, 2026Restricted and Performance Stock Units
Peter Rahmer
Officer
Aug 26, 202650,000$1.03MAug 26, 2026Restricted Stock Units
Pauling (Cayman) Ltd SVF
Stockholder
Aug 25, 20266,000,000$123.42MAug 25, 2026Acquired upon the automatic conversion of Series C Convertible Preferred Stock upon the closing of the Issuer's initial public offering. The shares were acquired and fully paid for in December 2018.
Sekar Kathiresan
Director
Aug 4, 202642,225$826.47KAug 4, 2026Stock Option Exercise
Sekar Kathiresan
Director
Jul 31, 202630,000$563.55KJul 31, 2026Stock Option Exercise
Sekar Kathiresan
Director
Jul 21, 202630,000$594.41KJul 21, 2026Stock Option Exercise
Sekar Kathiresan
Director
Jul 20, 202666,055$1.29MJul 20, 2026Stock Option Exercise
Sanjiv Patel
Director, Officer
Jul 7, 2026144,597$2.73MJul 7, 2026Restricted Stock Units
Peter Rahmer
Officer
Jun 30, 202650,000$987.00KJun 30, 2026Performance Stock Units
Thomas Catinazzo
Officer
Jun 22, 2026204,880$3.25MJun 22, 2026Exercise of Stock Options
Donald A. Bergstrom
Officer
Jun 22, 2026110,646$1.76MJun 22, 2026Exercise of Stock Options
Thomas Catinazzo
Officer
May 14, 202637,234$492.23KMay 14, 2026Restricted and Performance Stock Units
Thomas Catinazzo
Officer
Mar 9, 202653,151$525.66KMar 9, 2026Restricted Stock Units
Peter Rahmer
Officer
Oct 29, 202521,394$160.44KOct 29, 2025Restricted Stock

Congress trades

1 trade in Relay Therapeutics reported by 1 member of the House

MemberTypeTradedAmountFiled
Daniel Goldman
NY10
SoldJul 12, 2023$1K–15KAug 13, 2023

See a number that looks wrong?